CAR-T cell therapy: Science
Principles
The science it rests on, with why each principle matters to it
Relies on- Acquired immunity and antibodies Killer T cells normally destroy a cell only when they recognise both a foreign marker and the body's own molecules, as Doherty and Zinkernagel found [6]; a CAR gives them antibody-type targeting instead [2].
- The genetic code The T cells are given a new gene, and their own machinery reads it to build the receptor [3].
as of 2026-11-11
Discoveries
The discoveries that made it possible: when, by whom and what was found
| Year | Who | What |
|---|---|---|
| 1973 | Peter Doherty and Rolf Zinkernagel | Killer T cells must recognise both a virus and the body's own molecules to kill an infected cell (work of 1973 to 1975) [6] |
| 1975 | Georges Köhler and César Milstein | The hybridoma technique for making monoclonal antibodies [7] |
| 1989 | Gideon Gross, Tova Waks and Zelig Eshhar | Chimeric receptors that give T cells antibody-type targeting [2] |
as of 2026-11-11
The science explained
The science behind it explained for a curious reader
T cells are the immune system's security guards. Each carries receptors that check other cells for signs of trouble, but they only react when the trouble is shown to them in a particular way, alongside the body's own molecules [6]. Many cancer cells slip past. Antibodies work differently: they can grab a chosen marker on any cell directly, and since 1975 scientists have been able to make antibodies to order [7]. A chimeric antigen receptor brings antibody-type targeting to a T cell [2]. A T cell carrying it can recognise a marker such as CD19 on a leukaemia cell, switch on, kill the cell and then copy itself, so the dose keeps working inside the body [4].
as of 2026-11-11
Sources
- Expression of immunoglobulin-T-cell receptor chimeric molecules as functional receptors with antibody-type specificity Proceedings of the National Academy of Sciences (Gross, Waks, Eshhar), record at MIGAL, 1989
- FDA Approves Novartis' CAR-T Drug, First Gene Therapy Approval in US Pharmaceutical Technology, 2017
- FDA Approves Personalized Cellular Therapy for Advanced Leukemia (news release) Penn Medicine, 2017
- The Nobel Prize in Physiology or Medicine 1996 - Press release Nobel Assembly at Karolinska Institutet, 1996
- The Nobel Prize in Physiology or Medicine 1984: press release Nobel Assembly at Karolinska Institutet (nobelprize.org)